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Abstract: Hepatocellular carcinoma (HCC) is a serious public health hazard. Polygenes involvement, accumulation of 
genetic and epigenetic changes and immune response of viral vector during gene therapy have resulted in the high mortal-
ity rate without marked change. To provide a safeguard for gene therapy and the feasibility for a clinical application, ef-
forts have been focused predominantly upon constructing liver-targeted vector recently. MicroRNAs (miRNAs), a class of 
short endogenous RNAs, regulate the gene expression at the post-transcriptional level through imperfect base pairing with 
the 3-untranslated region of target mRNAs. miRNAs, especially the liver-specific miRNA: miR-122, have multiple func-
tions in liver development and abnormal expression of miRNAs could lead to liver diseases. Altered miRNA expressions 
have been observed in HCCs, viral hepatitis and hepatic ﬁbrosis. The different expression profiles of miRNAs in HCC 
suggest that miRNAs may serve as either novel potential targets acting directly as oncogenes or therapeutic molecules 
working as tumor suppressor genes. Moreover, the abundance in general and liver specificity in particular, all together 
make them attractive to be considered as elements for hepatic specific targeting viral vector. This review describes recent 
progress in miRNA investigation on liver associated for better understanding the relationship between miRNA and liver 
cancer in order to raise prospects for therapy. 
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INTRODUCTION 
  Hepatitis, hepatic fibrosis and hepatocellular carcinoma 
(HCC) are the main liver diseases, threatening the health of 
human beings. Especially, HCC is one of the most common 
cancers worldwide and among the leading causes of cancer-
related death [1] arises in the setting of chronic liver dis-
eases, mostly related to viral hepatitis B and C [2-4] and cir-
rhosis [5]. As other malignant diseases, polygenes involve-
ment coupled with accumulation of genetic and epigenetic 
changes [6-8] contribute to high mortality rate without 
marked changes, although unflagging effort has been de-
voted to study the molecular pathogenesis of HCC. 
  Many factors including exposure to hepatitis viruses [9-
11], foodstuffs contaminated with aﬂatoxin B1(AFB1) [12], 
heavy alcohol intake [13], nonalcoholic fatty liver disease 
[14], oral contraceptives [15] and hemochromatosis [16] can 
lead to HCC. However, the exact pathophysiology of HCC is 
poorly understood. Underlying liver dysfunction a predispos-
ing condition for HCC is the only thing we can confirm [5]. 
As a matter of fact, the predisposing condition for HCC 
dramatically changes the cellar signaling pathways, many 
genetic and epigenetic aberrations and the corresponding 
alterations in molecular pathways have been observed in the 
process of HCC. The involved pathways are depicted as fol-
lows: (a) activation of the Wnt/Frizzled/-catenin pathway  
 
 
*Address correspondence to this author at the Engineering Research Center 
of Molecular Medicine, Ministry of Education, 518/519 Shengjun Building, 
Huaqiao University Main Campus, 362021, China; Tel: 0086-0595-
22691632/22690535; Fax: 0086-0595-22690952;  
E-mail: ruianxu@hqu.edu.cn 
through mutations in -catenin as well as up-regulation of 
upstream elements, such as Frizzled receptors [17-21], (b) 
alteration of the MAPK signaling pathway through HBV or 
HCV infection [22,23], (c) activation of the JAK/STAT 
pathway through inactivation of JAK-binding proteins [24-
26], (d) inactivation of the tumor suppressor gene p53 
through gene mutation and posttranscriptional interaction 
with viral proteins as well as oxidative stress [27-29], (e) 
alteration of the tumor suppressor retinoblastoma (pRb 
Pathway) and p16INK4 genes through mutations or pro-
moter methylation [19-21], and (f) alteration of the trans-
forming growth factor- pathway [19-20]. 
  So far, many HCC-related oncogenes, including AFP, 
RAS, c-FOS, c-JUN, RHO, TGF-a, HGF, CerbB2, HER-2, 
HER-2/neu,  NEU,  NGL,  MDM2,  MMP, and IGF-,  have 
been found. The abnormal expression of these genes with 
regard to a lasting cell proliferation results in carcinogenesis 
ultimately [30]. 
  There is a long way to go in fighting against HCC. 
Among all the therapies available for HCC, the surgical re-
section and liver transplantation are currently best curative 
options to treat liver cancer. The high frequency of tumor 
recurrence and metastasis after curative resection is the ma-
jor obstacle in the process of HCC treatment. Statistics show 
that the survival rate of patients who have had a resection is 
30% to 40% at 5 years, postoperatively [10]. Chemotherapy 
and radiotherapy, the two conventional therapies applied in 
the treatment of cancer, also get an unfavorable score be-
cause of the resistance of HCC. Moreover, occurrence of 
HCC often coupled with liver dysfunction, leads to restrict 312    Current Genomics, 2010, Vol. 11, No. 5  Zhang et al. 
the use of conventional chemotherapeutics as there is more 
or less non-selective toxicity with significant systemic side 
effects [31]. Viral vectors, for example, recombinant adeno-
associated virus (rAAV), mediated gene therapy which is 
targeting liver by hydrostatic pressure injection, is consid-
ered to be the appealing approach for liver disease as it is 
quite effective, associated with higher infectious rate and 
prolonged expression. However, immune response induced 
by viral vector coupled with the expression of heterologous 
gene in unwanted tissues or cells could shut down the func-
tion gene expression [30]. Other experimental treatment ap-
proaches, including hormonal therapy, biologic and bio-
chemical therapy [32-36], and molecularly targeted therapy 
[37-40], are still needed to be further vertified in clinical 
application. There is an urgent need to develop novel treat-
ments for recurrent and advanced HCC.  
  A major endeavor to develop novel treatments should 
comprise the use of molecular
 profiling to characterize tu-
mors and provide accurate predictions as well as potential 
therapeutic targets during the process of HCC. miRNAs, an 
abundant class of endogenous, small, noncoding RNAs, 
19~25 nucleotides, can regulate the expression of protein-
coding genes at the posttranscriptional level through imper-
fect base pairing with the -untranslated region (3-UTR) of 
target mRNAs. After the discovery of the first miRNA in the 
roundworm Caenorhabditis elegans by Victor Ambros [41], 
these short regulatory RNAs have been verified to be an 
abundant class of RNAs in plants, primates, rodents, birds, 
fishes, worms and flies (http://microrna. sanger. ac.uk/). 
Large DNA viruses have also been found to carry miRNA 
genes: 5 in Epstein–Barr virus, 12 in Kaposi sarcoma-
associated herpesvirus, 9 in mouse g-herpes-virus 68, and 9 
in human cytomegalovirus [42]. miRNAs are post-
transcriptional regulators of genes involved in the develop-
mental timing, signaling pathways, apoptosis, metabolism, 
carcinogenesis and brain development [43]. Accumulating 
evidences have addressed that miRNAs are also involved in 
oncogene and tumor suppressor pathways [44-47]. Aberrant 
expression and structural alterations of miRNA genes have 
been found in a variety of tumor types [48-56]. 
  miRNAs in liver, the regulators of genes, wear different 
expression profiles from nondiseased livers to that among 
the patients with HCC including those with cirrhosis and 
hepatitis infection [57-59]. The different expression of 
miRNAs between the normal liver and diseased liver might 
lead to a novel direction, which is helpful not only for diag-
nosis, but also for novel therapeutic targets in liver cancer 
therapy. 
miRNA IN LIVER CANCER BIOLOGY 
  As extensively reviewed, the regulation of microRNA 
biogenesis (Fig. 1) contributes to ﬁne-tuning of the cellular 
phenotype, including proliferation, cell signaling, and apop-
tosis; Undoubtedly, miRNAs involve in liver cancer biology. 
miRNA Expression Profiles in HCC 
  Increasing evidence indicated that aberrant expression of 
miRNAs plays an essential role in the pathogenesis of can-
cer, either by controlling the expression of known protein-
coding genes, or by interacting with oncogenes or tumor 
suppressors [49]. Therefore, the expression profiles of miR-
NAs should play important roles in identifying their exact 
function in liver cancer biology, which may provide valuable 
information for diagnosis, classiﬁcation, progression, and 
even strategy for therapy [60]. 
  A study based on the miRNA expression proﬁles in 25 
pairs of HCC and adjacent nontumorous tissue (NT) using a 
human miRNA microarray suggests that miRNA may poten-
tially serve as a diagnostic tool of HCC. By comparing 
miRNA expression among HCC tissues versus the corre-
sponding non-cancerous liver tissues, 30 miRNAs (Table 1) 
had statistical differences with 3 miRNAs (Table 1) 
signiﬁcant up-regulation and 5 miRNAs signiﬁcant down-
regulation in HCC, respectively [57]. The accuracy of pre-
diction in the samples as HCC or NT reached 97.8% (45/46) 
by using support vector machine algorithms based on these 
data provided above. Another study on the miRNA expres-
sion in 10 pairs of HCC and adjacent NT from 10 non-viral 
hepatitis patients, using a mammalian miRNA microarray 
containing whole human mature and precursor miRNA se-
quences disclosed that 15 miRNAs exhibited higher expres-
sion and one miRNA demonstrated lower expression in the 
HCC samples than in the NT samples, respectively [61]. 
Besides, it is very amazing to find that among a total of 18 
miRNAs identiﬁed valid expression only in HCC samples, 
with 6 only in NT samples [61]. Jiang also showed that 16 
miRNAs including miR-199a, miR-21, miR-223, and miR-
150 were differentially expressed in the tumor compared 
with adjacent benign liver with 7 miRNAs up-regulation and 
5 miRNAs signiﬁcant down-regulation (Table 1) [58]. The 
potential use of miRNA profiling in subtyping human
 can-
cers to provide more accurate prognosis and prediction of
 
response to therapy are illustrated in the article by Ji, they 
found that the expression of miR-26a and miR-26b in non-
tumor liver tissue which is higher in women than in men, 
was reduced in a subgroup of samples from patients with 
liver cancer during their study. Furthermore, patients with 
reduced miR-26 expression
  had significantly reduced sur-
vival during a 6-year period but
 were more likely to have a 
response to adjuvant therapy with
 interferon alfa [62]. How-
ever, the expression pattern of certain miRNAs has not pre-
sented the same among these reports. Maybe it is due to the 
differences in samples, testing methods and even the non-
identical analytical methods. Nevertheless, the expression of 
hsa-miR-195 is down-regulation in some studies [57], while 
up-regulation in others [61]. 
  In addition, the expression proﬁles of certain miRNAs 
can also characterize the metastasis of HCC [67-68]. By ex-
amining the miRNA expression profiles of 482 cancerous 
and noncancerous specimens from radical resection of 241 
patients with HCC, Budhu built a unique 20-miRNA metas-
tasis signature that could significantly predict primary HCC 
tissues with venous metastases from metastasis-free solitary 
tumors with 10-fold cross-validation [68]. Zhang found that 
up-regulated miR-143 also enhances hepatocarcinoma me-
tastasis by repressing fibronectin expression [67]. Moreover, 
recent studies have documented that miRNAs may serve as 
either novel potential targets acting directly as oncogenes 
[69] or therapeutic molecules working as tumor suppressor 
genes [70]. Therefore, methods for liver cancer classification 
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ficity would prove to be very high-efficiency, succinct and 
rapid. 
Liver Associated miRNAs and p53 Tumor Suppressor 
Network 
  The aberrant expression of miRNAs in liver cancer may 
be attributing to the modulation of cancer-associated tran-
scription factors. Nowadays, there is a clearer picture emerg-
ing from the miRNA processing [71-73]. What develops our 
interest is the relationship between miRNA processing and 
p53 tumor suppressor networks [74-77]. The p53 protein is a 
transcription factor that regulates multiple cellular processes 
in tumor development, either by regulating mRNA directly 
or by regulating miRNA indirectly. Therefore, the relation-
ship between p53 and miRNA processing is of prime impor-
tance in the understanding of tumorigenesis.  
  By now, accumulating studies have addressed that miR-
NAs are the components of tumor suppressor pathways. An 
interesting case is represented by miR-34 family. miR-34 
family are direct transcriptional targets of p53, whose induc-
tion by DNA damage and oncogenic stress depends on p53 
both in vitro and in vivo [78,79]. Study carried out by Song 
further indicated that miR-192 may be another miRNA can-
didate that is involved in the p53 tumor suppressor network 
with significant effect on cell cycle control and cell prolifera-
tion [75]. To identify the regulation mechanisms in 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Biogenesis and Regulation of miRNA. 
Transcription from the miRNA gene in the nucleus, the pri-miRNA is then cleaved by Drosha and DGCR8, producing a precursor molecule 
(pre-miRNA). With the help of Exportin-5 and Ran-GTP, the pre-miRNA is transported to the cytoplasm. In cytoplasm, the pre-miRNA is 
cleaved by the ribonuclease Dicer to generate a short RNA duplex. The mature single-stranded miRNA is incorporated into the RNA-
induced silencing complex (RISC) to carry out the regulation function. The regulation mechanism conducting by miRNA dependents on the 
degree of complementarity between the 3-UTR region of the target mRNA and this so called ‘seed region’ in the 5-end of the miRNA, If 
there is perfect complementarity, then the mRNA is cleaved by RISC. If there is imperfect complementarity, regulation is carried out by re-
pression of translation in P-body. 314    Current Genomics, 2010, Vol. 11, No. 5  Zhang et al. 
Table 1.  miRNA Expression Proﬁles in HCC Compared with Normal Liver 
Liver-tumor dysregulation 
miRNA Class  miRNA  Murakami 
(2006) [57] 
Jiang 
(2008) [58] 
Huang 
(2008) [61] 
Ladeiro 
(2008) [63] 
Su 
(2009) [64] 
Gramantieri 
(2007) [65] 
Huang 
(2009) [66] 
Special in 
HCC 
[61] 
miR-18 Up  Up             
hsa-miR-18 
precursor miR-18  Up               
hsa-miR-21 miR-21    Up Up Up         
hsa-miR-33 miR-33    Up             
hsa-miR-101 miR-101    Down      Down       
miR-130b   Up         Up   
hsa-miR-130 
miR-130a           Down  Up  
hsa-miR-135 miR-135a    Up             
hsa-miR-139 miR-139    Down             
hsa-miR-150 miR-150    Down             
miR-199a Down  Down         Down  
miR-199a* Down  Down              hsa-miR-199 
miR-199b   Down            
miR-200a Down            Down  
miR-200b   Down             hsa-miR-200 
miR-200c      Down        
hsa-miR-214 miR-214    Down             
hsa-miR-221 miR-221    Up          Up   
hsa-miR-223 miR-223    Down             
hsa-miR-301 miR-301    Up             
hsa-miR-224 miR-224  Up      Up      Up   
hsa-miR-125 miR-125a  Down            Down   
hsa-miR-235 miR-235      Down           
hsa-miR-22 miR-22      Up           
miR-126    Up       Down   
mmu-miR-126 
miR-126-3p    Up  Down         
let-7b     Up      Down  Down   
let-7c     Up      Down  Down   
let-7g     Up      Down  Down   
let-7i     Up      Down  Down   
let-7f     Up      Down  Down   
let-7d     Up      Down  Down   
let-7e     Up      Down  Down   
let-7a-1    Up     Down  Down   
let-7a-2    Up     Down  Down   
hsa-let-7 
let-7a-3    Up     Down  Down   
hsa-miR-124 miR-124a-2            Down  Down   
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Liver-tumor dysregulation 
miRNA Class  miRNA  Murakami 
(2006) [57] 
Jiang 
(2008) [58] 
Huang 
(2008) [61] 
Ladeiro 
(2008) [63] 
Su 
(2009) [64] 
Gramantieri 
(2007) [65] 
Huang 
(2009) [66] 
Special in 
HCC 
[61] 
hsa-miR-132 miR-132            Down     
hsa-miR-136 miR-136            Down     
hsa-miR-141 miR-141            Down     
hsa-miR-142 miR-142            Down  Down   
hsa-miR-143 miR-143            Down  Down   
hsa-miR-145 miR-145            Down     
hsa-miR-150 miR-150            Down     
hsa-miR-155 miR-155            Down     
miR-181a-1          Down    
miR-181a-2          Down     hsa-miR-181 
miR-181c          Down    
hsa-miR-122 miR-122a            Down Down   
hsa-miR-98 miR-98      Up           
rno-miR-352 miR-352      Up           
hsa-miR-195 miR-195  Down    Up        Down   
hsa-miR-523 miR-523                Yes 
hsa-miR-34  miR-34a           Yes 
rno-miR-146 miR-146                Yes 
hsa-miR-121 miR-121                Yes 
hsa-miR-526 miR-526a                Yes 
hsa-miR-30 miR-30d                Yes 
hsa-miR-146 miR-146b                Yes 
hsa-miR-148 miR-148a                Yes 
rno-miR-17 miR-17              Up  Yes 
hsa-miR-215 miR-215                Yes 
hsa-miR-192 miR-192                Yes 
hsa-miR-93 miR-93                Yes 
hsa-miR-107 miR-107              Up  Yes 
hsa-miR-29  miR-29a           Yes 
hsa-miR-103 miR-103                Yes 
hsa-miR-146 miR-146a                Yes 
hsa-miR-15  miR-15a         Down  Yes 
hsa-miR-203 miR-203        Down         
hsa-miR-10 miR-10b        Up         
hsa-miR-222 miR-222        Up      Up   
hsa-miR-375 miR-375        Down         
hsa-miR-96 miR-96        Up         
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p53-associated miRNA processing, Suzuki showed that p53 
facilitates the processing of primary miRNAs to precursor 
miRNAs by interacting with the Drosha processing complex 
through the association with DEAD-box RNA helicase p68 
[71].  
  In turn, miRNA can also directly regulate p53. Le firstly 
demonstrated that miR-125b as a negative regulator of p53 
represses p53 protein levels in a manner dependent on its 
binding site in the p53 3 UTRs [76]. The conclusion reached 
by the a fact that overexpression of miR-125b represses the 
endogenous level of p53 protein and suppresses apoptosis in 
human neuroblastoma cells, while knockdown of miR-125b 
elevates the level of p53 protein and induces apoptosis in 
human lung fibroblastsin. Fornari further showed that miR-
122 can also directly regulate p53 by influencing p53 protein 
stability and transcriptional activity [80]. As the details of 
these and other miRNA biogenesis and regulatory processes 
unravel, the coming years promise to be an exciting time in 
miRNA-based liver cancer research. 
miRNAs AND VIRAL HEPATITIS 
  Viral hepatitis, the major preventable cause of HCC, is a 
significant medical and public health concern not only in 
China, but also throughout the world. It causes signiﬁcant 
morbidity and mortality [81]. Viral hepatitis is caused by 
infection with at least five distinct viruses, of which the three 
most commonly identified in the United States are hepatitis 
A virus (HAV), hepatitis B virus (HBV), and hepatitis C 
virus (HCV) [82]. Viral hepatitis can be very serious. By 
now, nearly 2 billion people ever infected with the hepatitis 
B virus (HBV) worldwide [83], and 350 million suffering 
from chronic HBV infection accounting for 320 000 deaths 
per year [84]. As for viral hepatitis C, an estimated 3% of the 
world’s population—more than 170 million people — are 
infected by HCV, resulting in 10,000 to 20,000 deaths a year 
in the United States [85]. Currently, therapeutics available 
for viral hepatitis, including Interferon alpha (IFN-), Pegin-
terferon-alpha-2a (PEG IFN-) and Ribavirin still could not 
control the disease completely, Furthermore, both interferon 
or ribavirin are expensive and often cause severe side effects, 
limiting their broader use and underscoring a novel therapeu-
tics to improve treatment outcomes. 
  Development of novel therapeutics should be based on 
the clear understanding of the exact mechanism in transcrip-
tional activity and replication activity of hepatitis virus, es-
pecially HBV and HCV. As hoped for, such studies have 
drawn much attention recently. A growing body of evidence 
has documented that epigenetic changes may be relevant to 
occult HBV infection [60, 86]. Further study suggests that 
methylation at HBV cccDNA island 2 might be correlated 
with the impaired replication activity of HBV cccDNA, 
which provides further evidence that methylation of hepatitis 
B virus covalently closed circular DNA may modulates HBV 
replication [87].  
  In addition, there is a clear evidence to confirm that 
miRNAs also participate in the regulation activity of HBV. 
Data based on computational approaches showed that one 
viral mRNA was found to be targeted by the viral miRNA 
indicating that HBV may use viral miRNAs to regulate its 
own gene expression [88]. Uprichard further demonstrated 
that HBV replication and gene expression can be strongly 
inhibited by virus specific siRNA treatment [89], setting 
light on the use of RNAi in HBV gene therapy. However, the 
high sequence specificity of siRNAs, combined with pro-
longed treatment, promoted the emergence of siRNA-
resistant virus variants. An improved study by using artificial 
miRNA (amiRNA) expression vector based on the murine 
miR-155 sequence shows that amiRNA could effciently sup-
press the expression and replication of HBV in vitro without 
the emergence of siRNA-resistant virus variants [90]. An-
other case in point is that by using Pol II promoter cassettes 
that transcribe anti-HBV primary miRNA (pri-miR-122) and 
pri-miR-31 shuttles, HBV replication is inhibited efficiently 
both in vitro and in vivo [91]. 
  HCV is an enveloped, positive-strand RNA virus of the 
Hepacivirus genus with a genome of about 9.6 Kb encoding 
a polyprotein of approximately 3,000 amino acids [92]. HCV 
exhibits considerable genetic diversity, but the HCV 5non-
coding region (NCR) plays an important role in viral replica-
tion and translation activity is highly conserved. A recent 
study aimed at integrating RNA structure and functional 
analysis of the 5NCR of HCV suggested that the 5NCR 
domain I plays an important role in RNA translational 
efﬁciency [93]. Liu’s study addressed that cyclophilin A 
(CyPA), a cellular chaperone with peptidylprolyl-cis-trans-
isomerase activity facilitates the replication of HCV RNA by 
forming specialized membrane structures through a recruit-
ing mechanism [94]. 
  Furthermore, progress in HCV investigation on siRNA 
and miRNA associated indicated, that RNA interference 
(RNAi) may be a promising therapeutic entity for viral infec-
tions. Since, the HCV genome is a single-stranded RNA that 
functions as both a template for transcription and template 
for a negative strand replication intermediate, it is a prime 
candidate for RNAi. Especially, the internal ribosome entry 
site (IRES) locating at the 5noncoding region of the viral 
genome, the highly conserved sequence and important roles 
in translation make it as an ideal target for RNAi, which has 
been documented in many studies [95-98].  
  As a potential therapeutic entity for viral infections, 
miRNA will never be inferior to siRNA, if not better. So far, 
there is still no evidence to confirm that HCV could utilize 
self-coding miRNAs to regulate its own gene expression, but 
miRNAs from the host cells may play an essential role in the 
regulation activity of HCV. A charming case in point is rep-
resented by miR-122, a liver-specific miRNA. miR-122 has 
been addressed to facilitate the replication of HCV by target-
ing the viral 5non-coding region [99]. The conclusion 
reached by the fact that HCV RNA can replicate in Huh 7 
cells, which express miR-122, but not in HepG2 cells, which 
do not express miR-122 [99]. Further study [100] carried out 
by the same team reveals an important fact that the location 
of the miR-122 binding site in the Hepatitis C Virus RNA 
Genome indicates its effect on gene regulation as insertion of 
the HCV miR-122 binding sites into the 3NCR of a reporter 
mRNA leads to downregulation of mRNA expression [100], 
while miR-122 interacts with the 5end of the hepatitis C 
virus RNA genome, resulting in increased viral RNA [99].  
  In addition, miR-122 can indirectly facilitate HCV repli-
cation by down-regulation of heme oxygenase-1 (HO-1) Therapeutics Based on microRNA  Current Genomics, 2010, Vol. 11, No. 5    317 
expression [101], HO-1 can suppress Hepatitis C Virus rep-
lication [102]. Therefore, down-regulation of miR-122 and 
up-regulation of HO-1 may be new strategies for anti-HCV 
intervention and cytoprotection. At the same time, transla-
tion of HCV RNA is also certainly correlated with miR-122. 
Sequestration of miR-122 in liver cell lines strongly reduces 
HCV translation, whereas addition of miR-122 stimulates 
HCV translation in liver cell lines and the non-liver HeLa 
cells [103].  
  Among other miRNAs, miR-199a*, another liver-specific 
miRNA with a sequence similar to the HCV genome has 
been identified as a potential inhibitor of HCV replication 
[104]. Different from miR-122, overexpression of miR-
199a* inhibited HCV genome replication, inhibition of miR-
199a*; however, accelerated viral replication. 
miRNAs AND HEPATIC FIBROSIS 
 Liver  ﬁbrosis characterized by an activation of hepatic 
stellate cells (HSCs) is another cause accounting for HCC. 
HSCs are the principal liver cells that promote hepatic 
ﬁbrosis [105]. Normally, residing in the space of Disse, 
HSCs can be activated by inﬂammation associated with 
inﬂammatory cytokines—including tumor necrosis factor  
(TNF-), IL-6, CC-chemokine ligand 2/monocyte chemoat-
tractant protein (MCP)-1, interleukin (IL)-1, and TGF- 
[106]. While some of inﬂammatory cytokines exert its effec-
tiveness in hepatic ﬁbrosis by inflencing the expression of 
liver ﬁbrosis associated miRNAs [107,108]. Nowadays, the 
point of view that liver ﬁbrosis can be reversal has been gen-
erally accepted [109] provided that the activated HSCs 
switch to a more quiescent HSC. Here we capture key ad-
vances in miRNA-based liver ﬁbrosis study in order to raise 
potentials for therapy. 
  HSCs contain bunches of vitamin A-riching lipid drop-
lets, while activated HSCs lose cytoplasmic lipid droplets 
and trans-differentiate to proliferative, and ﬁbrogenic 
myoﬁbroblasts play an essential role in the formation of liver 
ﬁbrosis [105]. A recent study based on down-regulation of 
miR-27a and 27b, two miRNAs that over-expressed in pri-
mary culture-activated rat HSCs documented that the cul-
ture-activated rat HSCs switch to a more quiescent HSC 
phenotype, with restored cytoplasmic lipid droplets and de-
creased cell proliferation [110]. Different from miR-27a and 
27b, miR-29a and 29b are often downregulated in the forma-
tion of liver ﬁbrosis, in vitro study showed that miR-29 as 
novel antiﬁbrogenic mediators can repress collagen synthesis 
[111]. Although, it is the only example available, it may 
raise the curtain at the age of miRNA –based liver ﬁbrosis 
therapy. 
LIVER-SPECIFIC miRNA SIGNATURES IN LIVER 
DISEASE 
  Certain miRNAs are expressed ubiquitously, whereas 
others are expressed in a highly tissue-specific manner [112]. 
miR-122 accounting for 70% of the total miRNA population, 
is one of the birds specifically and abundantly expressed in 
the liver with undetected in all other tissues [112,113].  
  There is a long way to identify the liver-specific 
miRNA:miR-122. As the precursor for miR-122 was discov-
ered in 1989. Furthermore, systematic cloning and sequenc-
ing of small RNAs prepared from dierent mouse tissues 
revealed that miR-122 was an abundant miRNA in the liver. 
The further study addressed that miR-122 is found in mouse, 
woodchuck and human livers, in human primary hepato-
cytes, and in cultured liver-derived cells, such as mouse 
Hepa 1-6 cells and human Huh7 cells [114]. Studies based 
on computational tools showed that the putative miR-122-
target genes involved in cellular stress response [113], hepa-
tocarcinogenesis [65, 115] and viral infection [99, 103], 
which were further experimentally conﬁrmed in cultured 
hepatocytes. 
  miR-122 plays an important role in the pathology of 
various diseases, including cancer, infection and metabolism 
disease. Analysis of RNAs from 20 human HCC samples 
showed that miR-122 was signiﬁcantly downregulated in 
50% of the tumors compared to non-malignant liver tissue 
from the same individuals [116], which is reconfirmed by 
others [117]. Further study shows that miR-122 also plays an 
important role in intrahepatic metastasis. Overexpression of 
miR-122 by a lentiviral vector (lenti-122) in metastatic Mah-
lavu and SK-HEP-1 cells signiﬁcantly reduced in vitro mi-
gration, invasion, and anchorage-independent growth as well 
as in vivo tumorigenesis, angiogenesis, and intrahepatic me-
tastasis in an orthotopic liver cancer model [118].  
  Moreover, the infection of the hepatitis C virus (HCV) 
was also dependent on the status of miR-122 expression [99, 
103]. A study carried out by Catherine L showed that HCV 
RNA can only replicate in cells expressing miR-122, but the 
replication failed to function. The role of miR-122 in HCV 
RNA replication was confirmed by silencing miR-122 in 
Huh7 cells with a marketed loss of replicating result [99]. At 
the same time, translation of HCV RNA is also certainly 
correlated with miR-122. Sequestration of miR-122 in liver 
cell lines strongly reduces HCV translation, whereas addition 
of miR-122 stimulates HCV translation in liver cell lines as 
well as in the non-liver HeLa cells and rabbit reticulocyte 
lysate. Further evaluating the role of miR-122 reveals that 
miR-122 stimulates HCV translation by enhancing the asso-
ciation of ribosomes with the viral RNA at an early initiation 
stage [103]. 
  The overall importance of miR-122 in the regulation of 
metabolism has been elaborated through an antisense strat-
egy speciﬁc to miR-122 so far [119]. Hepatic steatosis can 
be strikingly reduced in high-fat fed mice by silencing miR-
122 in an antisense strategy based on a 2-OMe phos-
phorothioate-modiﬁed oligonucleotide [119]. Similarly, si-
lencing miR-122 also resulted in an increase in expression of 
several hundred genes, which were notably represented as 
putative miR-122 target genes, including those that are nor-
mally repressed in hepatocytes, as well as a decrease in ex-
pression of several genes, including those that are involved 
in cholesterol biosynthesis [119]. All these results argued for 
the importance of miR-122 in maintaining an adult-liver 
phenotype by regulating the expression of non-liver genes. 
  As mentioned above, Liver-specific miRNA (miR-122) 
plays very important roles in the pathology of various liver 
diseases, which also implies miR-122 might serve as a po-
tential therapeutic target. For instance, therapeutics based on 
inhibiting miR-122 have proven to be efficient in inhibiting 318    Current Genomics, 2010, Vol. 11, No. 5  Zhang et al. 
viral replication both in vitro and in vivo over the last several 
years [91, 120]. The importance in function [119] and con-
venience in regulation [120-123], all together make thera-
peutics based on miR-122 attractive to be used in the liver 
disease. One potential therapeutic application comes from 
the eect of miR-122 antagomir in high-fat fed mice to re-
duce hepatic steatosis, which may provide an interesting 
opportunity to treat patients with non-alcoholic steatohepati-
tis [119]. Another interesting application of miR-122 an-
tagomir contributes in taking advantage of its eect on the 
down-regulation of adult-liver genes expression to generate 
in vitro a new attractive expandable cell source for hepato-
cyte transplantation that would feature stem/progenitor cell 
phenotype [119]; the third attracting application of miR-122 
antagomir contributes in inhibiting viral replication and 
translation, which may provide an interesting opportunity to 
treat patients with viral infection [99, 103]. 
miRNAs AS GENERAL ANTICANCER THERAPEU-
TICS  
  miRNAs modulating gene expression through sequence 
complementarity can influence a series of biological proc-
esses, including differentiation, proliferation, apoptosis, an-
giogenesis, invasion and metastasis. As the deregulation of 
these very same processes is a hallmark of cancer, on one 
hand, it directly suggests that miRNAs may work as putative 
tumor suppressor genes or oncogenes, and on the other hand, 
it indirectly indicates that efforts for cancer therapy should 
be focused on these putative tumor suppressor genes or on-
cogenes. Increasing data have documented the possibility 
that miRNAs-based treatment may be as promising antican-
cer therapeutics [70]. Here, we summerize the evidence 
available in HCC. 
  To date, accumulating evidences have addressed that the 
putative tumor suppressor miRNAs may be the novel thera-
peutic entity for HCC, particularly for miR-26a [70], which 
is normally expressed at high levels in normal adult liver but 
dramatic downregulation in both human and murine liver 
tumors. A study based on miR-26a replacement by using 
AAV as delivery vector potently suppresses cancer cell pro-
liferation and activates tumor-speciﬁc apoptosis in vivo, 
leading to dramatic suppression of tumor progression with-
out toxicity, as miR-26a induces a G1 arrest in human liver 
cancer cells by downregulating cyclins D2 and E2 [70]. 
Similarly, in HCC, Osteopontin (OPN) is identiﬁed as one of 
the leading genes that promote the metastasis of HCC [124]. 
A recent study based on lentiviral vectors encoding mi-
croRNA against OPN reveals that silencing OPN can dra-
matically inhibits in both in vitro invasion and in vivo lung 
metastasis of HCCLM3 cells, even could suppress in vitro 
proliferation and in vivo tumor growth of HCCLM3 by inter-
rupting MAPK pathway and NF-B pathway [125], which 
suggests that OPN could be a hopeful target for the control 
of metastasis as well as HCC tumor growth and viral vector-
mediated microRNA against OPN can be treated as a new 
therapeutics. 
  Among other putative tumor suppressor miRNAs, miR-
101 [64, 126], miR-122 and miR-223 are of particular inter-
est. The miR-101 is significantly down-regulated in the ma-
jority of cancer cell lines and cancer tissues examined. By 
targeting Mcl-1 [64], an antiapoptotic member of Bcl-2 fam-
ily [127], and repressing the expression of the FOS oncogene 
[126], miR-101 not only suppresses colony formation in vi-
tro and tumorigenicity in vivo but also sensitizes cancer cells 
to apoptosis induced by various chemotherapeutic drugs. 
Therefore, miR-101 could be a hopeful target for not only 
anticancer therapy but also a prognostic molecular marker 
for diagnose. The liver-speciﬁc miRNA, miR-122, could be 
detected as early as 12.5 days post-implantation and reaches 
a plateau immediately before birth [113], suggesting that 
miR-122 may play a critical role in liver development. Re-
cent studies [65,118] showed that miR-122 is significantly 
down-regulated in liver cancer, which may function as tumor 
suppressor. By restoring miR-122 in metastatic Mahlavu and 
SK-HEP-1 cells, migration, invasion in vitro as well as tu-
morigenesis, angiogenesis, and intrahepatic metastasis in 
vivo are significantly inhibited [118]. Further study ad-
dressed that miR-122 inhibits hepatocellular carcinoma in-
trahepatic metastasis by modulating ADAM17 (a disintegrin 
and metalloprotease 17), a key component in angiogenesis. 
Besides, miR-122 can target the 3-UTR of cyclin G1 
(CCNG1) mRNA for its regulation. An inverse correlation 
between miR-122 and CCNG1 exists in primary liver carci-
noma, further emphasizing the importance of miR-122 in 
HCC pathogenesis [65]. It is not more than a beginning. 
There are many novel miR-122 targets unidentified. A recent 
study by using miRNA-like siRNA expression vectors pro-
vides evidence that miR-122 can directly repress the Bcl-w 
protein level by targeting binding sites in the 3-UTR [128]. 
Furthermore, ADAM10 (a distintegrin and metalloprotease 
family 10), serum response factor (SRF), and insulin-like 
growth factor 1 receptor (Igf1R) were all validated as targets 
of miR-122 [129]. The study carried out by Coulouarn em-
phasized miR-122 as a diagnostic and prognostic marker for 
HCC progression, such a point of view reached by the fact 
that loss of miR-122 results in an increase of cell migration 
and invasion and that restoration of miR-122 reverses this 
phenotype [130,131]. In addition, the loss of miR-122 is as-
sociated with liver-enriched transcription factors, such as 
HNF1A, HNF3A and HNF3B [130]. All these data suggest 
miR-122 plays a very important role in liver cancer, which is 
also an attractive therapy target for liver cancer. Similar to 
miR-122, miR-223 is also significantly down-regulated in 
HCC. Re-expression of miR-223 in HBV, HCV, and non-
HBV non-HCV-related HCC cell lines revealed a consistent 
inhibitory effect on cell viability. Further study implicated 
that Stathmin 1 (STMN1) is a downstream target of miR-
223. The substantial reduction in STMN1 protein was dem-
onstrated upon restoration of miR-223 expression in HCC 
cell lines [132]. Therefore, miR-223 may represent a novel 
target in liver cancer therapy because it regulates STMN1, 
which is a good marker of the PTEN/PI3K path-way activity. 
  miRNAs, which are amplified or overexpressed in cancer 
could act as putative oncogenes or miRNAs that targets one 
or more tumor suppressor genes to inhibit the activity of an 
anti-oncogenic pathway. The miR-21 is one of the chief ac-
tors. Different from the putative tumor suppressor miRNAs 
mentioned above, miR-21 is always highly over-expressed in 
HCC [58, 61, 63, 117]. Inhibition of miR-21 in cultured 
HCC cells increased expression of the phosphatase and 
tensin homolog (PTEN) tumor suppressor, and decreased 
tumor cell proliferation, migration, and invasion [117]. Con-
sistent with the results, an increase in tumor cell prolifera-Therapeutics Based on microRNA  Current Genomics, 2010, Vol. 11, No. 5    319 
tion, migration, and invasion was observed in tumor cells 
transfected with precursor miR-21 [117]. Another study 
based on antisense oligonucleotides specific for miR-21 pre-
sented the idea that miR-21 played an important role in the 
maintenance of the malignant transformation of hepatocytes 
[133]. All these data showed that overexpression of miR-21 
can contribute to HCC growth and spread by modulating 
PTEN expression. PTEN is a direct target of miR-21 and 
silencing miR-21 maybe a newly attractive therapeutics. An-
other interesting case in consideration is miR-221, similar as 
reported in other tumors [134], miR-221 is observed to be 
up-regulated also in HCC. Besides, the previously reported 
targets p27 and p57 [135], miR-221 can inhibit apoptosis by 
targeting Bmf, up-expression coupled with affecting multiple 
pro-oncogenic pathways indicate that miR-221 is a potential 
target for nonconventional treatment against HCC [136]. In 
vivo study based on a mouse model of liver cancer carried 
out by Pineau et al. addressed that miR-221 overexpression 
stimulates growth of tumorigenic murine hepatic progenitor 
cells by turely regulating DNA damage-inducible transcript 
4 (DDIT4), a modulator of mTOR pathway [137]. Garofalo 
et al. further demonstrated that miR-221 could induce 
TRAIL resistance and enhance cellular migration through the 
activation of the AKT pathway and metallopeptidases by 
targeting PTEN and TIMP3 tumor suppressors [138]. 
  To sum up the points, therapeutics based on miRNA is a 
potential therapy for HCC, even most of the possible path-
ways regulated by these miRNAs are still unclear. However, 
it will not blurr the possibility of treating miRNAs as general 
anticancer therapeutics, as strategies based on either silenc-
ing or restoring a miRNA in suppression of tumor progres-
sion, migration, invasion tumorigenesis, angiogenesis, and 
intrahepatic metastasis prove to be significantly effective. 
Moreover, not only silencing a miRNA in using antisense 
oligonucleotides specific but also restoring a miRNA in us-
ing viral vectors proved to be perfectly available. Here, we 
can boldly give prophesy that therapeutics based on miRNA 
will have an infinitely bright future. 
miRNAs AND VECTOR LIVER-TARGETING  
  As stated, RNAi based on siRNA and miRNA could be 
one of the most promising avenues for the development of 
antiviral therapies and anticancer therapies. The success of 
RNAi in therapeutic application also depends on an efficient 
delivery system, which can support long-term siRNA pro-
duction and continuous gene silencing. So far, the most 
powerful gene therapy vectors come from viruses with sev-
eral steps of modification, as an ideal delivery system, gene 
therapy vector should be targeted specifcally such that they 
transduce target cells, while avoiding sequestration in other 
organs or toxicity from infection of unwanted cells. Consid-
erable methods including transcriptional targeting [139], 
transductional targeting [140] and translational targeting 
[141], have been used for vector targeting. However, none is 
effective to all the vectors. Vector targeting by engineering 
the cassettes to contain miRNA target (miRT) elements that 
can then be recognized and regulated by endogenous cellular 
miRNAs has greatly attracted much attention. Here, we pre-
sent the evidence available that miRNAs can be used for 
vector liver-targeting. 
  Nowadays, an increasing evidence suggested that tissue-
specific miRNAs play essential roles in regulating vector 
liver-targeting. One potential application comes from the 
impact of vector containing tissue-specific miRT elements in 
the specific tissue to shut down capsid genes expression, 
which provide an interesting opportunity to systematically 
reduce/eliminate the effects of potential contaminating from 
replication competent virus during virus vector-mediated 
gene therapy [142] (Fig. 2).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). Eliminate the effects of potential contaminating from replication competent AAV by tissue-specific miRNAs.  
Incorporation into a packaging plasmid (green) of target sequences (red) recognized by liver-specific miRNAs (purple) ensures that the repli-
cation competent virus can’t replicate in liver cells. 320    Current Genomics, 2010, Vol. 11, No. 5  Zhang et al. 
  Another interesting application of tissue-specific miR-
NAs consist in taking advantage of its eect on the down-
regulation of transgene expression in hematopoietic lineages 
to escape immune response. Currently, one of the major bar-
riers to stable gene transfer is the development of transgene-
speciﬁc immunity [143] because of the direct expression of 
the transgene product within professional antigen-presenting 
cells (APCs) of the immune system [144]. Even tissue-
speciﬁc promoters are used, immune reaction can still be 
observed. A recent study [145] based on lentiviral vectors 
encoding target sequences for hematopoietic specific mir-
142-3p documented that, by preventing transgene expression 
in hematopoietic lineages while permitting high levels of 
expression in nonhematopoietic cells, miRNA regulation 
could enable stable gene transfer in the absence of an im-
mune response [146]. The rational application was recon-
firmed by others [146-148]. 
  The third attractive application of tissue-specific miR-
NAs in vector liver-targeting comes from gene therapy, 
based on oncolytic viruses to reduce hepatotoxicity. By in-
corporating a casette that contains sequences complementary 
to the liver-speciﬁc miR-122 in the 3UTR of the E1A gene, 
the recombinant adenovirus replicated normally in other cells 
but not in cells of hepatic origin [149-151]. Moreover, sui-
cide gene therapy based on Ad vectors that mediate miR-
122a-regulated HSVtk expression can be more safe and effi-
cient by reducing hepatotoxicity perfectly [152].  
  As is known to all, miRNAs always signature in various 
diseases characterized by deregulation of miRNAs. Espe-
cially in cancer, oncogenic miRNAs are found to be ubiqui-
tously expressed in normal tissues, but highly enriched in 
tumors, while tumor suppressor miRNAs specifically down-
regulated in cancer. Therefore, target elements to be tumor 
suppressor miRNAs responsive engineered within a vector 
can increase gene silencing in normal tissue, leaving gene 
expressing in cancer specially. For example, let-7, miR-143 
and miR-145, as putative tumor suppressor miRNAs, are 
proved to be low expression in certain cancer cells [153]. 
The regulation based on either let-7 or miR-143 and miR-
145 endows wild-type viral tumor-specific replication while 
eliminates undesirable replication and associated toxicity in 
normal cells [154,155]. All these data suggest that vector 
targeting regulated by miRNA could be not only tumor-
specific but also few hepatotoxicity and immune response. It 
is therefore expected to be of a major utility for the genera-
tion of liver-targeted expression vectors. 
CONCLUSION AND PROSPECTIVE 
  Identification of miRNA function involved in liver can-
cer has provided an important knowledge regarding miRNA-
tumor associated gene interactions and revealed many poten-
tial therapeutic targets. As documented in many studies, 
some miRNAs may function as oncogenes while others act 
as tumor suppressors. For oncogenic miRNAs, such as miR-
21, a desirable therapeutic strategy, reduce their functions in 
cells. As for tumor suppress miRNAs, restoring that miRNA 
should provide the attractive outcome.  
  Despite remarkable progress in miRNA-based therapy, 
many questions remain to be answered. The first nut for us to 
crack is that we should have a clear understanding of the 
exact mechanism to be responsive to miRNA regulation and 
the physiological function in the course of the life cycle. It is 
rarely known very little about the cellular circuits controlled 
by miRNAs in general and by cancer-associated miRNAs in 
particular. Efforts should be made to check the true fre-
quency of mutations in miRNAs and in their target se-
quences. Besides, computational methods should be adopted 
to get a more comprehensive understanding of their mecha-
nism of action. Only in this way, can we get a clearer picture 
of the role of miRNAs in human cancer. Different miRNAs 
are expressed at different copy numbers, the same miRNA is 
expressed at different copy numbers in different cell linea-
ges. What interests us most is that the threshold copy of 
miRNAs must be reached to achieve appreciable gene silenc-
ing. However, there is less data available for reference.  
  As one of the most promising avenues for the develop-
ment of anticancer therapies, the success of miRNA in thera-
peutic application relies on an efficient delivery system. 
Nowadays, vector targeting is still one of the major barriers 
to achieve stable gene transfer. Gathering studies suggest 
vector targeting by engineering the cassettes to contain 
miRNA target (miRT) elements that could then be recog-
nized and regulated by endogenous cellular miRNAs is very 
effective and versatile, although, much work remains to be 
done on the exact number of copies and the spacing elements 
between tandem copies of miRT elements, which will prove 
the most effcacious for vector targeting. The rAAV mediated 
gene therapy is considered to be the appealing approach for 
liver disease. Nevertheless, immune response induced by 
capsid synthesis in targeting tissues from residual contami-
nating replication competent AAV particles often shut down 
the function gene expression. To systematically re-
duce/eliminate the effects of potential contaminating rcAAV 
particles, our laboratory designed a novel AAV helper 
(pH22mir) with a microRNA binding cassette containing 
multiple copies of liver specific (hsa-mir-122) and hema-
topoietic specific (has-mir-142-3p) sequences to specifically 
control cap gene expression [142]. In the liver, 99.9% of 
capsid expression could be suppressed and no cap expression 
could be detected by the Western blot. Overall, it is difficult 
to overestimate the potential impact of the regulatory circuits 
of miRNAs in the liver, which may provide attractive targets 
for treatment of liver cancer. 
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ABBREVIATIONS  
HCC =  Hepatocellular  carcinoma 
rAAV  =  Recombinant adeno-associated virus 
miRNA =  MicroRNA 
UTR =  Untranslated  region 
AFB1  = Aﬂatoxin B1 
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HAV  =  Hepatitis A virus 
HBV  =  Hepatitis B virus  
HCV =  Hepatitis  C  virus 
amiRNA =  Artifcial  miRNA 
NCR =  Non-coding  region 
CyPA =  Cyclophilin  A 
IFN- =  Interferon  alpha 
PEG IFN- =  Peginterferon-alpha-2 
RNAi =  RNA  interference 
IRES  =  Internal ribosome entry site 
HO-1 =  Heme  oxygenase-1 
OPN =  Osteopontin 
ADAM17  =  A disintegrin and metalloprotease 17 
CCNG1 =  Cyclin  G1 
ADAM10  =  A distintegrin and metalloprotease family 
10 
SRF  =  Serum response factor 
Igf1R  =  Insulin-like growth factor 1 receptor 
STMN1 =  Stathmin  1 
miRT =  miRNA  target 
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